首页 | 本学科首页   官方微博 | 高级检索  
     


Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy
Authors:Nadeem Q. Mirza MD   MPH  Georges Vlastos MD  Funda Meric MD  Thomas A. Buchholz MD  Nestor Esnaola MD   MPH  S. Eva Singletary MD  Henry M. Kuerer MD   PhD  Lisa A. Newman MD  Frederick C. Ames MD  Merrick I. Ross MD  Barry W. Feig MD  Raphael E. Pollock MD   PhD  Marsha McNeese MD  Eric Strom MD  Kelly K. Hunt MD
Affiliation:(1) Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 444, 77030 Houston, TX;(2) Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Abstract:Background Our aim was to identify predictors of locoregional recurrence (LRR) in patients with early-stage breast cancer treated with breast-conserving therapy (BCT) and long-term follow-up. Methods From 1970 to 1994, 1153 patients with stage I to II breast cancer underwent BCT and radiotherapy at our institution. Patients with prior breast cancer or other primary malignancies were excluded. Clinical and pathologic characteristics evaluated were age, race, tumor size, stage, pathologic tumor margins, axillary nodal involvement, estrogen and progesterone receptor status, Black's nuclear grade, type of surgery, and use of adjuvant therapy. Results Of 1083 patients, 54% presented with stage I disease and 46% with stage II disease. Median age was 50 years, and median follow-up was 9 years. Axillary nodes were positive in 31% of the patients who underwent axillary dissection. LRR developed in 6%, LRR followed by systemic recurrence in 5%, and systemic recurrence alone in 13%, 76% had no evidence of recurrence at last follow-up. Age, tumor size, positive lymph nodes, and not receiving chemotherapy or hormonal therapy were independent predictors of LRR. Disease-specific survival among patients with LRR was similar to that among patients with no recurrence. Conclusions Multidisciplinary treatment strategies should be used to accomplish durable locoregional control after BCT. Presented at the 54th Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, March 15–18, 2001.
Keywords:Breast neoplasms  Local recurrence  Predictors  Breast-conserving therapy  Survival
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号